Denise Myshko

Senior Editor, OncLive®
Denise Myshko is your editorial contact for the Oncology Business Management section of OncologyLive, as well as the corporate newsletters. She joined OncologyLive in March 2020. Before that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email:


No-Cost Counseling Can Address Psychosocial Needs of Patients With Cancer

September 25th 2021

Counseling, psychotherapy, and mental health services provide the opportunity to develop coping skills and inspire hope; however, patients often experience hurdles to accessing such care. Among these obstacles are cost, unawareness that programs exist, the COVID-19 pandemic, and other external factors.

Pushing the Envelope in Search of a Cure

August 29th 2021

In a box, ready to be unpacked in his new office, are all the things patients have given Robert L. Coleman, MD, over the years. They include a jug of beer from a brewery in Arkansas, a golden ship from Kuwait, bottles from Serbia, art and books, and even a signed picture of Weird Al Yankovic.

Investigators Look to Enhance Response With Novel Triplet in CLL

August 5th 2021

Investigators of the phase 3 ULTRA-V trial are look-ing to leverage the synergistic capabilities of venetoclax for patients with chronic lymphocytic leukemia with the addition of the U2 regimen of ublituximab in combination with umbralisib.

KRAS Pathway Opens Door for Patients With Difficult-to-Treat Ovarian Cancer

June 18th 2021

Dual blockade of the RAF/MEK and FAK pathways presents an opportunity for investigators to enhance and expand the number of patients with recurrent low-grade serous ovarian cancer who can benefit from targeted therapies.

Cetuximab Misses ORR End Point in RAS Wild-Type, BRAF V600E+ mCRC

June 7th 2021

The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mutant metastatic colorectal cancer.

Targeting CLL1-Positive Cells Shows Efficacy in Early Trial in Pediatric AML

June 6th 2021

Investigators validated the safety and efficacy of anti-C-type lectin-like molecule-1-based CAR T cells in a small clinical trial of pediatric patients with relapsed/refractory acute myeloid leukemia.

4-Year Findings Confirm Long-Term Benefit for Nivo/Ipi in First Line for mNSCLC

June 4th 2021

The combination of nivolumab and ipilimumab continued to provide a durable, long-term overall survival benefit compared with chemotherapy after 4 years for patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Daiichi Sankyo and Guardant Health Team Up for Companion Diagnostic for Trastuzumab Deruxtecan in Advanced NSCLC

May 27th 2021

Daiichi Sankyo Inc. is collaborating with Guardant Health Inc. to develop a companion diagnostic for fam-trastuzumab deruxtecan-nxki, which is being studied to treat patients with advanced metastatic HER2-mutated non‒small cell lung cancer.

Long-Term Neoadjuvant Study Tests Nivolumab in ER+/HER2- Breast Cancer

May 17th 2021

Investigators are evaluating the addition of nivolumab to standard neoadjuvant therapy in patients with high-risk, estrogen-receptor–positive/ HER2-negative breast cancer to determine whether the PD-1 immune checkpoint inhibitor can improve recurrence rates.

TIL Immunotherapy Shows Promise as Second-Line Treatment of NSCLC

May 12th 2021

Investigators are studying LN-145, a novel immunotherapy developed from autologous tumor-infiltrating lymphocytes, as a potential new option for patients with unresectable or metastatic non–small cell lung cancer after disease progression on a checkpoint inhibitor and chemotherapy.

Shortage of Cancer Care Providers in Rural Areas Affects Patient Outcomes

May 11th 2021

In the United States, a geographic mismatch exists between the number of medical oncology and radiation providers and patients needing care, with more specialists clustered in urban and metropolitan areas.

Amgen Acquires Five Prime for its Oncology Pipeline

April 28th 2021

Amgen has completed its planned acquisition of Five Prime Therapeutics for $38.00 per share in cash, or approximately $1.9 billion.

Tucatinib Combo Has Potential as Second-Line Option in HER2+ Gastric/GEJ Cancers

April 20th 2021

Investigators are exploring a dual HER2-targeting strategy that incorporates tucatinib into a novel combination as second-line therapy for patients with HER2-positive gastric and esophageal cancers.

Undetectable METex14 Following Savolitinib Is Associated with Higher PFS, OS in NSCLC

April 11th 2021

Patients with non‒small cell lung cancer whose circulating tumor MET Exon 14 is undetectable following treatment with savolitinb are more likely to have positive outcomes.

Investigators Launch Epidemiology Study in Younger Patients With NSCLC

April 9th 2021

Investigators have launched the Epidemiology of Young Lung Cancer study to identify risk factors that can help shed light on why lung cancer develops in the younger population.

Canadian Collaborative Launches to Provide Infrastructure for Cancer Cell Therapy Research

March 31st 2021

The Canada Foundation for Innovation has awarded C$5,187,685 to the Canadian Cancer Trials Group at Queen’s University in Kingston, Ontario, Canada, to fund the infrastructure for a new research platform to coordinate the development of new cancer cell therapies.

Study Tests Guidelines for Monitoring Pancreatic Cysts

March 30th 2021

Investigators are seeking to determine the optimal protocol for monitoring patients with pancreatic cysts to better identify neoplasms that are more likely to become malignant.

Diversity Gap Persists for Racial and Ethnic Minorities in Oncology

March 23rd 2021

Despite many diversity initiative over the past 10 years, a lack of meaningful representation of certain racial and ethnic minorities continues in the oncology workforce.

Investigators Focus Devimistat Study on Older Patients With AML

March 15th 2021

Devimistat, a small molecule that targets enzymes involved in cancer cell metabolism, holds promise for older patients with relapsed or refractory acute myeloid leukemia who typically have a poor prognosis with standard-of-care chemotherapy

Cardio-Oncology Strategies Can Improve Survivorship for Patients With Breast Cancer

March 9th 2021

Treatment strategies for patients with breast cancer, especially the combination of anthracyclines and HER2-targeted therapies, come with an increased risk of heart failure and cardiac toxicity.